Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: January 2010

19 - CEREBROVASCULAR COMPLICATIONS OF FABRY’S DISEASE

from PART II: - HEREDITARY AND GENETIC CONDITIONS AND MALFORMATIONS

Summary

This chapter investigates sarcoidosis-associated stroke syndromes. Sarcoidosis is often referred to as a "disease of exclusion". The definitive diagnosis of sarcoidosis requires histopathologic demonstration of noncaseating epithelioid granulomas that are not due to infection or malignancy. Patients can be classified as having possible, probable, or definite neurosarcoidosis based on the certainty of the diagnosis of multisystem sarcoidosis, the pattern of neurological disease, and the response to therapy. Corticosteroids are the mainstay of treatment for patients with symptomatic neurosarcoidosis; however, the severity and chronicity of this disease in some patients often leads to reluctance in subjecting patients to the long-term sequelae of corticosteroid treatment. Nonetheless, it is reasonable to decrease sarcoidosis-associated inflammation to decrease stroke risk. Anecdotal evidence suggests that concurrent use of corticosteroids and adjunctive agents is a reasonable approach. Antiplatelet agents has been used as a stroke-preventive strategy but have avoided thrombolytic interventions.

REFERENCES

Altarescu, G., Moore, D. F., Pursley, R., et al. 2001. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke, 32, 1559–62.
Altarescu, G., Moore, D. F., and Schiffmann, R. 2005. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology, 64, 2148–50.
Archer, B. W. C. 1927. Multiple cavernous angiomata of the sweat glands associated with hemiplegia. Lancet, ii, 595–6.
Avierinos, J.-F., Brown, R. D., Foley, D. A., et al. 2003. Cerebral ischemic events after diagnosis of mitral valve prolapse. Stroke, 34, 1339–44.
Bamford, J., Sandercock, P., Dennis, M., et al. 1991. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet, 337, 1521–6.
Barbey, F., Brakch, N., Linhart, A., et al. 2006. Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr, 95(Suppl 451), 63–8.
Barnett, H. J. M., Boughner, D. R., Taylor, D. W.et al. 1980. Further evidence relating mitral-valve prolapse to cerebral ischemic events. N Engl J Med, 302, 139–44.
Bass, B. H. 1958. Angiokeratoma corporis diffusum. Br Med J, 1, 1418.
Beck, M. 2006. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease. Acta Paediatr, 95(Suppl 451), 43–6.
Becker, A. E., Schoorl, R., Balk, A. G. and van der Heide, R. M. 1975. Cardiac manifestations of Fabry’s disease. Am J Cardiol, 36, 829–35.
Bethune, J. E., Landrigan, P. L. and Chipman, C. D. 1961. Angiokeratoma corporis diffusum universale (Fabry’s disease) in two brothers. N Engl J Med, 264, 1280–5.
Bird, T. D. and Lagunoff, D. 1978. Neurological manifestations of Fabry disease in female carriers. Ann Neurol, 4, 537–40.
Bogousslavsky, J., Van Melle, G., and Regli, F. 1988. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke, 19, 1083–92.
Brown, A. 1952. Diffuse angiokeratoma: report of two cases with diffuse skin changes, one with neurological symptoms and splenomegaly. Glasgow Med J, 33, 361–8.
Cable, W. J. L., Kolodny, E. H., and Adams, R. D. 1982. Fabry disease: impaired autonomic function. Neurology, 32, 498–502.
Chen, C. H., Shyu, P. W., Wu, S. J., et al. 1998. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online. Hum Mutat, 11, 328–30.
Cohen, I. S., Fluri-Lundeen, J., and Wharton, T. P. 1983. Two dimensional echocardiographic similarity of Fabry’s disease to cardiac amyloidosis: a function of ultrastructural analogy? J Clin Ultrasound, 11, 437–41.
Colley, J. R., Miller, D. L., Hutt, M. S. R., and Wallace, H. J. 1958. The renal lesion in angiokeratoma corporis diffusum. Br Med J, 1, 1266–8.
Crutchfield, K. E., Patronas, N. J., Dambrosia, J. M., et al. 1998. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology, 50, 1746–9.
Curry, H. B., Fleisher, T. L., and Howard, F. 1961. Angiokeratoma corporis diffusum–a case report. JAMA, 175, 864–8.
DeGraba, T., Azhar, S., Dignat-George, F., et al. 2000. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol, 47, 229–33.
De Groot, W. P. 1964. Angiokeratoma corporis diffusum Fabry. Dermatologica, 128, 321–49.
Desnick, R. J., Brady, R., Barranger, J., et al. 2003. Fabry disease, an under-recognized multi-systemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med, 138, 338–46.
Desnick, R. S., Ioannou, Y. A., and Eng, C. M. 2001. a-Galactosidase A deficiency: Fabry disease. In C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle, eds., The Metabolic Basis of Inherited Disease, 8th edn. New York: McGraw Hill; pp. 3733–74.
DiLorenzo, P. A., Kleinfeld, J., Tellman, W., and Nay, L. 1969. Angiokeratoma corporis diffusum (Fabry’s disese). Acta Derm Venereol, 49, 319–25.
Dobkin, B. H. 1989. Orthostatic hypotension as a risk factor for symptomatic occlusive cerebrovascular disease. Neurology, 39, 30–4.
Eng, C. M., Guffon, N., Wilcox, W. R., et al. 2001. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med, 345, 9–16.
Fellgiebel, A., Mazanek, M., Whybra, C., et al. 2006. Pattern of microstructural brain tissue alterations in Fabry disease. J Neurol, 253, 780–7.
Furlan, A. J., Craciun, A. R., Raju, N. R., and Hart, N. 1984. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke, 15, 282–4.
Ginsberg, L., Manara, R., Valentine, A. R., et al. 2006. Magnetic resonance imaging changes in Fabry disease. Acta Paediatr, 95(Suppl 451), 57–62.
Goldman, M. E., Cantor, R., Schwartz, M. F., et al. 1986. Echocardiographic abnormalities and disease severity in Fabry’s disease. J Am Coll Cardiol, 7, 1157–61.
Grewal, R. P., and Barton, N. W. 1992. Fabry’s disease presenting with stroke. Clin Neurol Neurosurg, 94, 177–9.
Grewal, R. P., and McLatchey, S. K. 1992. Cerebrovascular manifestations in a female carrier of Fabry’s disease. Acta Neurol Belg, 92, 36–40.
Guin, G. H., and Saini, N. 1976. Diffuse angiokeratoma (Fabry’s disease): case report. Mil Med, 141, 259–63.
Hasholt, L., Sorensen, S. A., Wandall, A., et al. 1990. A Fabry’s disease heterozygote with a new mutation: biochemical, ultrastructural, and clinical investigations. J Med Genet, 27, 303–6.
Ho, P. C. and Feman, S. S. 1981. Internuclear ophthalmoplegia in Fabry’s disease. Ann Ophthalmol, 13, 949–51.
Hughes, D. A., and Mehta, A. B. 2005. Vascular complications of Fabry disease: enzyme replacement and other therapies. Acta Paediatr, 94(Suppl 447), 23–33.
Igarashi, T., Sakuraba, H., and Suzuki, Y. 1986. Activation of platelet function in Fabry’s disease. Am J Hematol, 22, 63–7.
Jensen, E. 1966. On the pathology of angiokeratoma corporis diffusum (Fabry). Acta Pathol Microbiol Scand, 68, 313–31.
Kahn, P. 1973. Anderson–Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatr, 36, 1053–62.
Kaye, E. M., Kolodny, E. H., Logigian, E. L., and Ullman, M. D. 1988. Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann Neurol, 23, 505–9.
Kleijer, W. J., Hussaarts-Odijk, L. M., Sachs, E. S., et al. 1987. Prenatal diagnosis of Fabry’s disease by direct analysis of chorionic villi. Prenat Diagn, 7, 283–7.
Kleinert, J., Dehout, F., Schwarting, A., et al. 2006. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens, 19, 782–7.
Kramer, W. J., Thormann, J., Mueller, K., and Frenzel, H. 1985. Progressive cardiac involvement by Fabry’s disease despite successful renal allotransplantation. Int J Cardiol, 7, 72–5.
Lou, H. O. C., and Reske-Nielsen, E. 1971. The central nervous system in Fabry’s disease. Arch Neurol, 25, 351–9.
Maisey, D. N., and Cosh, J. A. 1980. Basilar artery aneurysm and Anderson–Fabry disease. J Neurol Neurosurg Psychiatr, 43, 85–7.
Marino, S., Borsini, W., Buchner, S., et al. 2006. Diffuse structural and metabolic brain changes in Fabry disease. J Neurol, 253, 434–40.
Medin, J. A., Tudor, M., Simonovitch, R., et al. 1996. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci USA, 93, 7917–22.
Mendez, M. F., Stanley, T. M., Medel, N. M., Li, Z., and Tedesco, D. T. 1997. The vascular dementia of Fabry’s disease. Dement Geriatr Cogn Disord, 8, 252–7.
Menzies, D. G., Campbell, I. W., and Kean, D. M. 1988. Magnetic resonance imaging in Fabry’s disease. J Neurol Neurosurg Psychiatr, 51, 1240–1.
Mitsias, P., and Levine, S. R. 1996. Cerebrovascular complications of Fabry’s disease. Ann Neurol, 40, 8–17.
Moore, D. F., Altarescu, G., Barker, W. C., et al. 2003. White matter regions in Fabry disease occur in ‘prior’ selectively hypometabolic and hyperperfused brain regions. Brain Res Bull, 62, 231–40.
Moore, D. F., Altarescu, G., Herscovitch, P., and Schiffmann, R. 2002. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol, 2, 4.
Moore, D. F., Gelderman, M. P., Fuhrmann, S. R., et al. 2006. Fabry disease and vascular risk factors: future strategies for patient-based studies and the knockout murine model. Acta Paediatr, 95(Suppl 451), 69–71.
Moore, D. F., Scott, T. C. S., Gladwin, M. T., et al. 2001. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease. Circulation, 104, 1506–12.
Moore, D. F., Ye, F., Brennan, M., et al. 2004. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging, 20, 674–83.
Morgan, S. H., Rudge, P., Smith, S. J. M., et al. 1990. The neurological complications of Anderson–Fabry disease (a-galactosidase A deficiency). Investigation of symptomatic and presymptomatic patients. Q J Med, 75, 491–504.
Moumdjian, R., Tampieri, D., Melanson, D., and Ethier, R. 1989. Anderson–Fabry disease: a case report with MR, CT, and cerebral angiography. Am J Neuroradiol, 10, S69–70.
Mutoh, T., Senda, Y., Sugimura, K., et al. 1988. Severe orthostatic hypotension in a female carrier of Fabry’s disease. Arch Neurol, 45, 468–72.
Nishide, M., Irino, T., Gotoh, M., et al. 1983. Cardiac abnormalities in ischemic cerebrovascular disease studied in two-dimensional echocardiography. Stroke, 14, 541–5.
Nishizaki, T., Tamaki, N., Takeda, N., et al. 1986. Dolichoectatic basilar artery: a review of 23 cases. Stroke, 17, 1277–81.
Ohsugi, K., Kobayashi, K., Itoh, K., Sakuraba, H., and Sakuragawa, N. 2000. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector. J Hum Genet, 45, 1–5.
Oto, S., Kart, H., Kadayifcilar, S., Ozdemir, N., and Aydin, P. 1998. Retinal vein occlusion in a woman with heterozygous Fabry’s disease. Eur J Ophthalmol, 8, 265–7.
Petersen, R. C., Garrity, J. A., Houser, O. W. 1989. Fabry’s disease: an unusual cause of stroke with unique angiographic findings. Neurology, 39(Suppl. 1), 123.
Pompen, A. W. M., Ruiter, M., and Wyers, H. J. G. 1947. Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. Acta Med Scand, 128, 234–55.
Prüss, H., Bohner, G., and Zschenderlein, R. 2006. Paroxysmal vertigo as the presenting symptom of Fabry disease. Neurology, 66, 249.
Roach, E. S. 1989. Congenital cutaneouvascular syndromes. In J. F. Toole, ed., Handbook of Clinical Neurology, vol. II (55): Vascular Diseases, Part III. Amsterdam–New York: Elsevier Science Publishers B.V., pp. 443–62.
Rolfs, A., Böttcher, T., Zschiesche, M., et al. 2005. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet, 366, 1794–6.
Russel, J. W., Biller, J., Hajduczok, Z. D., et al. 1991. Ischemic cerebrovascular complications and risk factors in idiopathic hypertrophic subaortic stenosis. Stroke, 22, 1143–7.
Sakuraba, H., Igarashi, T., Shibata, T., and Suzuki, Y. 1987. Effect of vitamin E and ticlopidine on platelet aggregation in Fabry’s disease. Clin Genet, 31, 349–54.
Sakuraba, H., Yanagawa, Y., Igarashi, T., et al. 1986. Cardiovascular manifestations in Fabry’s disease. A high incidence of mitral valve prolapse in hemizygotes and heterozygotes. Clin Genet, 29, 276–83.
Schatzki, P. F., Kipreos, B., and Payne, J. 1979. Fabry’s disease. Primary diagnosis by electron microscopy. Am J Surg Pathol, 3, 211–9.
Schiffman, R., Koff, J. B., Austin, H. A., et al. 2001. Enzyme replacement therapy in Fabry disease. JAMA, 285, 2743–9.
Schwartz, A., Rautenberg, W., and Hennerici, M. 1993. Dolichoectatic intracranial arteries: review of selected aspects. Cerebrovasc Dis, 3, 273–9.
Scully, R. E., Mark, E. J., and McNeely, B. U. 1984. Case records of Massachusetts General Hospital: case 2, 1984. N Engl J Med, 310, 106–14.
Sher, N. A., Reiff, W., Letson, R. D., and Desnick, R. J. 1978. Central retinal artery occlusion complicating Fabry’s disease. Arch Ophthalmol, 96, 815–7.
Spada, M., Pagliardini, S., Yasuda, M., et al. 2006. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Med Genet, 79, 31–40.
Steward, V. W., and Hitchcock, C. 1968. Fabry’s disease (Angiokeratoma corporis diffusum). Pathol Eur, 3, 377–88.
Stoughton, R. B., and Clendenning, W. E. 1959. Angiokeratoma corporis diffusum (Fabry). Arch Dermatol, 79, 601–2.
Tagliavini, F., Pietrini, V., Gemignani, F., et al. 1982. Anderson–Fabry’s disease: neuropathological and neurochemical investigation. Acta Neuropathol (Berlin), 56, 93–-8.
Takenaka, T., Hendrickson, C. S., Tworeck, D. M., et al. 1999. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol, 27, 1149–59.
Takenaka, T., Sakuraba, H., Hashimoto, K., et al. 1996. Coexistence of gene mutations causing Fabry disease and Duchenne muscular dystrophy in a Japanese boy. Clin Genet, 49, 255–60.
Tedeschi, G., Bonavita, S., Banerjee, T. K., Virta, A., and Schiffmann, R. 1999. Diffuse central neuronal involvement in Fabry disease. A proton MRS imaging study. Neurology, 52, 1663–7.
Topaloglou, A. K., Ashley, G. A., Tong, B., et al. 1999. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med, 5, 806–11.
Utsumi, K., Seta, T., Katsumata, T., et al. 2006. Effect of selective LDL-apheresis in a Fabry patient with recurrent strokes. European Journal of Neurology, 13, 429–30.
Utsumi, K., Yamamoto, N., Kase, R., et al. 1997. High incidence of thrombosis in Fabry’s disease. Intern Med, 36, 327–9.
Wallace, R. D., and Cooper, W. J. 1965. Angiokeratoma corporis diffusum universale (Fabry’s disease). Am J Med, 39, 656–61.
Wise, D., Wallace, H. J., and Jellinek, E. H. 1962. Angiokeratoma corporis diffusum. Q J Med, 122, 177–206.
Yokoyama, A., Yamazoe, M., and Shibata, A. 1987. A case of heterozygous Fabry’s disease with a short PR interval and giant T waves. Br Heart J, 57, 296–9.
Zeluff, G. W., Caskey, C. T., and Jackson, D. 1978. Heart attack or stroke in a young man? Think Fabry’s disease. Heart Lung, 7, 1056–61.